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ADHD has been considered a childhood neurodevelopmen-
tal disorder, characterized by symptoms, including inatten-
tion, impulsivity, and hyperactivity (Davidson, 2008; 
Goldman, Genel, Bezman, & Slanetz, 1998). In recent 
years, evidence has shown that in 30% to 70% of patients 
with ADHD during childhood, the disorder persists into 
adulthood (Lara et al., 2009; Mannuzza, Klein, & Moulton, 
2003; Pary et al., 2002; Silver, 2000). Different from pre-
sentation of this disorder in children, symptoms of hyperac-
tivity among adults with ADHD diminish, whereas 
symptoms of inattention persist and may affect important 
functions in life. Adult patients with ADHD may also expe-
rience interpersonal problems and coexisting psychiatric 
and substance abuse disorders (Volkow & Swanson, 2013). 
Considering the significant consequences of ADHD among 
adults, it is important to examine the epidemiology of the 
diagnosis and treatment of ADHD in adults.
Although ADHD is well studied in the pediatric popula-
tion, little is known about ADHD diagnosis and treatment in 
adults. Reported prevalence rates of diagnosed ADHD 
among adults vary across a limited number of available 
studies, which have used different methodological 
approaches and different samples of patients (Almeida 
Montes, Hernández García, & Ricardo-Garcell, 2007; 
Faraone & Biederman, 2005; Heiligenstein, Conyers, 
Berns, Miller, & Smith, 1998; Holden et al., 2013; Kessler 
et al., 2006; Knight et al., 2014; McCarthy et al., 2012; 
Montejano, Sasané, Hodgkins, Russo, & Huse, 2011; 
Simon, Czobor, Bálint, Mészáros, & Bitter, 2009). Early 
studies of small sample size estimate the prevalence of 
ADHD diagnosis mainly by examining self-reported symp-
toms or via structured interviews based on the Diagnostic 
and Statistical Manual of Mental Disorders (4th ed.; 
DSM-IV; American Psychiatric Association [APA], 1994) 
criteria (Almeida Montes et al., 2007; Faraone & Biederman, 
2005; Heiligenstein et al., 1998; Kessler et al., 2006; 
McCarthy et al., 2012; Simon et al., 2009). To date, limited 
number of studies have reported population-based estimates 
in adults (Holden et al., 2013; Knight et al., 2014; McCarthy 
et al., 2012; Montejano et al., 2011), and no study has esti-
mated the prevalence of ADHD diagnosis and treatment in 
adult Medicaid beneficiaries. Furthermore, most popula-
tion-based studies have required presence of both ADHD 
diagnosis and treatment to determine the prevalence of the 
disorder, which may underestimate true prevalence, as 
treatment discontinuation is common. In terms of the 
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Abstract
Objective: To estimate the prevalence of adult ADHD diagnosis and treatment in U.S. Medicaid beneficiaries. Method: 
Using outpatient, inpatient, and pharmacy billing records for patients eligible for Medicaid fee-for-service benefits within 29 
states from 1999 to 2010, we estimated the annual prevalence of ADHD diagnosis and treatment. Results: The prevalence 
of ADHD diagnosis increased from 2.20 per 1,000 patients in 1999 to 10.57 in 2010. Likewise, prevalence of ADHD 
treatment increased from 1.95 per 1,000 patients in 1999 to 13.16 in 2010. Between 40% and 65%, patients had ADHD 
drug prescription fills 6 months after ADHD diagnosis, whereas 45% to 55% of the beneficiaries with an ADHD drug 
prescription fill had ADHD diagnoses within 6 months before the prescription. Conclusion: In publicly insured adults, the 
prevalence of ADHD diagnosis and treatment increased dramatically over the years. Approximately half of the diagnosed 
patients are not treated, whereas half of the treated adults are not diagnosed. (J. of Att. Dis. 2018; 22(2) 182-190)
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prevalence of ADHD treatment among adults, majority of 
the previous studies only reported prevalence of treatment 
in young adults (age ≤20; Barry, Martin, & Busch, 2012; 
Johansen, Matic, & McAlearney, 2015; McCarthy et al., 
2009). Only one study reported ADHD treatment rate in 
adults aged 20 years and older (Castle, Aubert, Verbrugge, 
Khalid, & Epstein, 2007).
To address the gaps in the existing literature, the goal of 
this study was to estimate the prevalence of diagnosed adult 
ADHD and its treatment in U.S. Medicaid beneficiaries, as 
well as to examine proximate relationships between pre-
scribing ADHD medications and ADHD diagnosis.
Method
Study Design
We conducted a repeated cross-sectional study using 
Medicaid Analytic eXtract (MAX) files of 29 states to 
identify all adult Medicaid beneficiaries in fee-for-service 
(FFS) and primary care case management (PCCM) plans 
aged 18 to 64 years. The MAX data are a set of patient-
level data files that provide monthly information on 
patients’ Medicaid eligibility, demographics, diagnoses, 
and medical procedures performed at outpatient and inpa-
tient settings as well as medication dispensing records sub-
mitted for reimbursement.
Definitions
ADHD patients were identified based on having at least one 
inpatient or two outpatient visits with International 
Classification of Disease, Version 9, Clinical Modification 
(ICD-9-CM) diagnosis code of 314.xx (314.00—attention 
deficit disorder without mention of hyperactivity, 314.01—
attention deficit disorder with hyperactivity, 314.1—hyper-
kinesis with developmental delay, 314.2—hyperkinetic 
conduct disorder, 314.8—other specified manifestations of 
hyperkinetic syndrome, and 314.9—unspecified hyperki-
netic syndrome) in each specific study year.
ADHD medication use was determined based on having 
at least one prescription fill record of an ADHD medication. 
ADHD medications included all dosage forms of methyl-
phenidate, mixed amphetamine salts, pemoline, and the 
nonstimulant medication atomoxetine.
Statistical Analysis
We report four estimates involving ADHD diagnosis and 
treatment using different eligibility requirements, and 
numerator and denominator definitions (Table 1). For each 
year from 1999 through 2010, we identified all individuals 
18 to 64 years old who were continuously enrolled in 
Medicaid for the entire 12 months of the measurement year 
(e.g., from January 1-December 31, 2001). The annual 
prevalence of ADHD was then calculated as the proportion 
of eligible patients who had at least one inpatient or two 
outpatient service claims with ICD-9-CM code 314.xx. The 
annual prevalence of ADHD medication use was calculated 
as the proportion of eligible patients who had at least one 
pharmacy claim for an ADHD medication in the study year. 
We stratified estimates of ADHD diagnosis and ADHD 
medication use prevalence by age and gender, and the prev-
alence of ADHD medication use by methylphenidate, 
mixed amphetamine salts, and atomoxetine preparations.
To estimate the prevalence of treatment in patients with 
diagnosed ADHD, we identified patients who had at least 
one inpatient or two outpatient service claims with ICD-
9-CM code 314.xx in the first half of the calendar year (i.e., 
January 1-June 30). We then followed these patients for 6 
months starting from the date of their ADHD diagnosis to 
determine the proportion of patients who had at least one 
pharmacy claim for an ADHD medication during the fol-
low-up period. In each annual cohort, eligible patients were 
required to have at least 6 months of continuous eligibility 
after the date of their first ADHD diagnosis. Reversing the 
approach of the previous analysis, we also estimated the 
proportion of patients who had at least one ADHD diagno-
sis in the 6-month period before their first dispensing of an 
ADHD medication in the second half of a calendar year 
Table 1. Numerator and Denominator Definitions for Prevalence Estimates.
Prevalence/percentage Numerator Denominator
Annual prevalence of ADHD Number of patients with ≥1 inpatient 
or 2 outpatient ADHD diagnoses
Number of adults with 12-month continuous 
eligibility in Year X
Annual prevalence of ADHD drug use Number of patients with ≥1 ADHD 
prescription claim
Number of adults with 12-month continuous 
eligibility in Year X
Percentage of patients who had 
ADHD prescription claims 6 months 
after ADHD diagnosis
Number of patients with ≥1 ADHD 
prescription claim within 6 months of 
follow-up
Number of eligible ADHD patients with 
6-month continuous eligibility after ADHD 
diagnosis in the first half of Year X
Percentage of patients who had 
ADHD diagnosis 6 months before 
their ADHD prescription claim
Number of patients with ≥1 in- and 
2 outpatient ADHD diagnoses 6 
months before prescription claim
Number of eligible patients with 6-month 
continuous eligibility 6 months before ADHD 
prescription claim in the second half of Year X
184 Journal of Attention Disorders 22(2) 
(i.e., July 1-December 31). Thus, in each calendar year, we 
required eligible patients to have at least 6 months of con-
tinuous enrollment before their first ADHD treatment phar-
macy claim.
SAS Version 9.4 (SAS Institute, Cary, North Carolina) 
was used to perform the data management and statistical 
analyses. The study was approved by the Institutional 
Review and Privacy Boards at the University of Florida and 
the Centers for Medicare & Medicaid Services.
Results
From 1999 to 2010, we identified approximately 1,288,942 to 
2,571,952 eligible adults in each year, with 34.22% to 39.88% 
females and the average age ranged from 39.03 to 40.39 years 
(Table 2). The prevalence of adult ADHD diagnosis increased 
approximately fivefold from 2.20 per 1,000 patients in 1999 to 
10.57 per 1,000 patients in 2010 (Figure 1). Likewise, the prev-
alence of ADHD treatment increased considerably from 1.95 
per 1,000 patients in 1998 to 13.16 per 1,000 patients in 2010 
(Figure 1). Notably, in the later study years, the annual preva-
lence of ADHD treatment use surpassed the ADHD preva-
lence. Overall, the prevalence estimates of ADHD diagnosis 
and ADHD medication use increased across all age groups 
from 1999 to 2010 (Figures 2 and 3). Prevalence of both diag-
nosis and medication use showed a consistent age trend with 
the largest prevalence in younger age groups. Compared with 
females, male patients showed higher prevalences of both 
ADHD diagnosis and medication use, but the prevalence rate 
ratio for females comparing prevalence in 2010 to prevalence 
in 1999 was slightly higher than that of males, with 5.6 versus 
3.9 for ADHD diagnosis and 7.6 versus 5.9 for ADHD medi-
cation use (Figure 4).
Comparing utilization pattern of the various ADHD 
medications, the prevalence of methylphenidate use 
increased from 1.21 per 1,000 patients in 1999 to 4.50 per 
1,000 patients in 2010, whereas the prevalence of mixed 
amphetamine salts use increased disproportionally from 
0.50 per 1,000 patients in 1999 to 6.98 per 1,000 patients in 
2010 (Figure 5). The prevalence of atomoxetine use 
increased from 0.90 per 1,000 patients in 2003 to a peak 
with 2.23 per 1,000 patients in 2005, which was followed 
by a decrease to 1.68 per 1,000 patients in 2010.
Over the study period, approximately 40% to 65% of 
patients with an ADHD diagnosis in the first half of the 
Table 2. Demographic Characteristics of Study Samples by Year.
Characteristics
Year
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Sample size (n) 1,952,942 2,035,380 2,178,294 2,171,520 2,571,952 2,462,090 2,275,483 1,775,431 1,437,463 1,342,189 1,288,942 1,313,374
Age (%) 39.75 39.86 39.21 39.23 39.22 39.12 39.03 40.29 40.39 39.92 39.86 39.43
 18-25 18.36 18.05 19.79 19.33 19.66 20.00 20.26 18.67 19.12 20.14 19.10 19.75
 26-35 21.62 21.27 21.74 22.01 21.87 22.05 22.27 19.72 19.33 20.16 21.40 22.30
 36-45 22.84 23.14 22.59 22.86 22.27 21.71 21.06 20.44 19.45 18.66 19.10 18.63
 46-55 19.41 20.05 19.76 19.98 20.30 20.49 20.66 23.11 23.29 22.89 22.91 22.61
 55 and older 17.76 17.48 16.12 15.82 15.90 15.75 15.74 18.06 18.80 18.16 17.49 16.70
Gender (%)
 Male 35.08 35.16 34.22 34.89 34.96 35.14 35.11 37.90 38.55 38.35 39.33 39.88
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Figure 2. Annual ADHD diagnosis prevalence among adults by 
age groups.
Zhu et al. 185
calendar year had at least one ADHD prescription fill claim 
in 29 U.S. states. Likewise, about 44% to 52% of all patients 
who filled an ADHD prescription had at least one inpatient 
or two outpatient service claims with a diagnosis of 314.xx 
during the 6 months before their ADHD prescription (Figure 
6). Both percentages increased over the years.
Discussion
This study examined the prevalence of ADHD diagnosis and 
treatment among adult Medicaid beneficiaries. The study 
results highlight four important insights in ADHD diagnosis 
and medication use among adults. First, in this study, the 
prevalence estimates of ADHD diagnosis were about twice 
of the estimates in previous studies using administrative 
databases in various geographic areas of the United States 
(Knight et al., 2014; Montejano et al., 2011). In a U.S. com-
mercial population with employer-sponsored insurance, 
the estimated prevalence was about 1.20 to 4.02 per 1,000 
patients from 2002 to 2007 (Montejano et al., 2011). The 
other study reported the prevalence of ADHD in a managed 
care population at 3.12 to 4.15 per 1,000 patients from 2006 
to 2009 (Knight et al., 2014). This could be partially 
explained by the different study populations. Compared with 
privately insured patients, Medicaid beneficiaries in general 
are of lower social economic status, which has been shown 
to be one of the causes or the consequences of mental disor-
ders (Hudson, 2005; Miech, Caspi, Moffitt, Wright, & Silva, 
1999). However, the higher prevalence rate we observed 
may be in part explained by different case definition such as 
the requirement to have both a diagnosis and pharmacologi-
cal ADHD treatment in the previous studies (Knight et al., 
2014). To avoid underestimating the prevalence caused by 
untreated ADHD among adults, we did not use prescription 
claims in addition to diagnosis claims to determine manifes-
tation of ADHD. When analyzing the proximity of diagnosis 
and treatment, we observed that only about 40% to 65% of 
the diagnosed patients had ADHD treatment within 6 months 
after diagnosis, which confirmed our concerns for untreated 
adult ADHD. Our findings provided insights on the mea-
surement of ADHD diagnosis among adults using automated 
databases in future research, which should take how adult 
ADHD and treatment were diagnosed and treated in the 
actual clinical setting into consideration. During the study 
periods of the existing studies on adult ADHD, including 
this study, the diagnosis of adult ADHD was guided by the 
DSM-IV. However, DSM-IV was criticized because the diag-
nostic criteria for ADHD were primarily focused on chil-
dren, which leads to underdiagnosis of many teens and 
adults with symptoms of ADHD (APA, 1994; Applegate 
et al., 1997). In 2013, Diagnostic and Statistical Manual of 
Mental Disorders (5th ed.; DSM-5; APA, 2013) was updated 
according to the evidence of the reduction in symptoms with 
increasing age. Adults as well as teens can now be diagnosed 
more easily because DSM-5 raises the age limit of when 
symptoms should be documented, that is, from age 7 to age 
12 and lowers the number of symptoms from 6 to 5 for diag-
nosis in individuals of age 17 and above (APA, 2013). With 
the implementation of DSM-5, the prevalence of adult 
ADHD after 2013 will be expected to be higher from what 
has been reported (Ghanizadeh, 2013).
Second, similar to other studies, we observed a substan-
tial increase in both the prevalence rates of ADHD diagno-
sis and treatment among adult Medicaid beneficiaries 
(Holden et al., 2013; Knight et al., 2014; McCarthy et al., 
2012; Montejano et al., 2011). In this study, we observed an 
approximately five fold relative increase in ADHD diagno-
sis and a seven fold relative increase in ADHD treatment in 
adult patients. This substantial increase in diagnosis of 
ADHD in adults could partially be explained by the fact that 
the prevalence of ADHD may have been influenced by 
modified diagnostic criteria among adults over time 
(Wender, Wolf, & Wasserstein, 2001). Furthermore, our 
findings reflect the increasing clinician and public recogni-
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Figure 3. Annual ADHD medication use prevalence among 
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Figure 4. Annual ADHD diagnosis and medication use 
prevalence among adults by gender.
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also raise concerns about the potential growth of the medi-
cal and economic burden related to ADHD in adults, espe-
cially in patients with low social economic status. In terms 
of prevalence of specific drug classes, mixed amphetamine 
salts had surpassed methylphenidate utilization at the end of 
the study period, where the prevalence of mixed amphet-
amine salts was one and a half times as large as the preva-
lence of methylphenidate. Atomoxetine use was on the 
decline across all 29 states with marginal prevalence rates 
in 2010. The fluctuation of the prevalence of atomoxetine 
use corresponds with the box warning issued by the Food 
and Drug Administration (FDA) for the potential side effect 
related to suicidal behavior/ideation in September 2005.
Third, the growth of ADHD diagnosis and treatment 
occurred across both genders and all age groups over the 
12-year study period. Compared with males, the prevalence 
of both diagnosis and treatment among females was lower, 
which were similar to what has been observed in children 
(Winterstein et al., 2008). However, the prevalence in females 
increased slightly faster than that in males. Compared with 
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Atomoxene 0 0 0 0 0.9 2.09 2.23 1.93 1.98 1.9 1.84 1.68
Mixed amphetamine salts 0.50 0.77 0.94 1.22 1.59 2.23 2.95 3.65 4.23 4.89 5.65 6.98
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Figure 6. Percentage of patients with ADHD medication after ADHD diagnosis and percentage of patients who had ADHD diagnosis 
before ADHD medication.
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older age groups, the highest prevalence in 18 to 25 age 
group can be explained by delayed diagnosis from childhood, 
persistence of ADHD from childhood, as well as the increased 
recognition and diagnosis of ADHD in the college-age popu-
lation. Some argue that the lower prevalence in older age 
groups could also be explained by improvement of hyperac-
tivity and impulsivity and increased compensation strategies 
over time (Biederman, Wilens, Spencer, & Adler, 2007; 
Jackson & Farrugia, 1997; Klein et al., 2012). However, 
according to survey-based studies using validated diagnostic 
tools, the prevalence of ADHD was estimated to be more 
than 3% among older adults (aged >55), which is much 
higher than the prevalence we observed (de Zwaan et al., 
2012; Goodman, Mitchell, Rhodewalt, & Surman, 2016; 
Guldberg-Kjär & Johansson, 2009; Michielsen et al., 2012). 
This suggests the relative absence of diagnosis and treatment 
of ADHD in patients above age 55 is much likely a reflection 
of lack of clinician training, appropriate symptom defini-
tions, and diagnostic tools for use among older adults in clini-
cal practice.
Finally, the annual prevalence of ADHD treatment use 
surpassed the ADHD prevalence in the later study years. 
Following the observation, about half of the patients who 
had ADHD treatment did not have a service claim with a 
diagnosis of 314.xx within 6 months before the pharmacy to 
dispense claim, which could be explained by a few possible 
reasons. First, studies have shown that physicians may be 
reluctant to label adult patients with psychiatric disorders 
without confirming the condition (Mitchell, 2007). ADHD 
medications are likely to be prescribed when a clinician is 
unsure of the diagnosis and uses the medication response as 
a clinical indicator of the condition, which may result in 
treatment without ADHD diagnosis. In addition, with only 
two diagnoses that are documented with an outpatient visit 
claim, it is conceivable that more prominent or more acute 
diagnoses took precedence, and thus, ADHD may have 
been present but not documented. On the contrary, ADHD 
medications may be prescribed for narcolepsy or off-label 
indications such as treatment-refractory depression, cancer 
fatigue, obesity, or other conditions symptomatic with a 
lack of motivation and apathy (Greenhill et al., 2002; Jeffers 
& Benotsch, 2014; Trenque, Herlem, Abou Taam, & Drame, 
2014). Given that previous studies reported prevalent non-
medical use and misuse of prescription stimulants among 
young adults (Kaye & Darke, 2012; McCabe, Knight, Teter, 
& Wechsler, 2005; Wilens et al., 2008), future research 
should address what alternative indications or purposes for 
ADHD medication use exist in this population.
Limitation
Our study is subject to a few limitations. In this study, we 
used ICD-9-CM diagnosis codes to identify ADHD 
diagnosis in medical encounter billing records, which has 
inherent limitations due to coding and billing errors. In addi-
tion, the accuracy of ADHD diagnosis depends on a number 
of factors, including clinician training and experience, time 
necessary for adequate evaluation of patients’ condition, as 
well as outside informants to increase specificity and sensi-
tivity of diagnosis (Asherson et al., 2010; Moncrieff & 
Timimi, 2010; Surman & Goodman, 2017). Thus, our preva-
lence estimate of ADHD diagnosis may not reflect the true 
prevalence among adults. Furthermore, we included patients 
from 29 states in the United States, representing the vast 
majority of patients enrolled in Medicaid FFS plans nation-
ally. We did not examine the prevalence in individual states 
and given demonstrated variability of ADHD diagnoses and 
treatment across states in children (Visser et al., 2015; 
Visser et al., 2014), we caution against extrapolating our 
results to individual states. Of note, sample sizes dropped 
drastically in the year 2006 because of increasing Medicaid 
managed care penetration and decreased number of FFS 
enrollees (Centers for Medicare & Medicaid Services, 
2013). In the present analysis, we restricted eligible benefi-
ciaries to those in FFS or PCCM plans from 1999 to 2010 
with no supplemental managed care plan other than dental 
because of concerns on completeness and quality of the 
encounter data of managed care plan. Thus, our results may 
have limited generalizability to Medicaid patients in other 
managed care plans.
Conclusion
In summary, this study reports the prevalence estimates of 
ADHD diagnosis and treatment using administrative data in 
Medicaid Analytic eXtract (MAX) billing records. The 
prevalence of adult ADHD diagnosis and medication use 
has increased substantially from 1999 to 2010 across both 
genders and all age groups. Approximately, half of the 
patients did not have a prescription claim within 6 months 
of the diagnosis whereas half of the patients on ADHD 
medications did not have a diagnosis 6 months before the 
treatment. These findings on ADHD diagnosis and treat-
ment emphasize the need for studies that examine the treat-
ment patterns of Adult ADHD and alternative diagnosis and 
purpose of ADHD medication use.
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